Skip to Content

'
Constance T. Albarracin, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1993 University of Illinois, Chicago, IL, PHD, Physiology
1984 University of Santo Tomas, Manila, Philippines, MD, Medicine

Experience/Service

Other Appointments/Responsibilities

Affiliate Faculty, The University of Texas MD Anderson Cancer Center Clinical Cancer Genetics, Houston, TX, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene 31(40):4372-83, 10/2012. PMCID: PMC3326223.
2. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 36(9):1353-8, 9/2012. PMID: 22895267.
3. Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Marchiò C, Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JS. Molecular Evidence in Support of the Neoplastic and Precursor Nature of Microglandular Adenosis. Histopathology 60(6B):E115-30, 5/2012. PMID: 22486256.
4. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Non-carriers: A Single Institution Experience. J Clin Oncol 29(28):3739-46, 10/2011. PMID: 21900106.
5. Shehu A, Albarracin C, Devi YS, Luther K, Halperin J, Le J, Mao J, Duan RW, Frasor J, Gibori G. The Stimulation of HSD17B7 Expression by Estradiol Provides a Powerful Feed-Forward Mechanism for Estradiol Biosynthesis in Breast Cancer Cells. Mol Endocrinol 25(5):754-66, 5/2011. PMCID: PMC3082328.
6. Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige N. Atypical Ductal Hyperplasia in Directional Vacuum-Assisted Biopsy of Breast Microcalcifications: Considerations for Surgical Excision. Ann Surg Oncol 18(3):752-61, 3/2011. PMID: 20972636.
7. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18(5):423-35, 11/16/2010. PMCID: PMC3022383.
8. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med 134(2):162-3; author reply 163, 2/2010. PMID: 20121597.
9. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High Prevalence of Pre-invasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prev Res (Phila) 2(2):122-7, 2/2009. PMID: 19174581.
10. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of Annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 12/2008. PMID: 18776816.
11. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CT. MicroRNA-196a targets Annexin A1: A microRNA-mediated mechanism of Annexin A1 downregulation in cancers. Oncogene 27(52):6667-78, 11/2008. PMID: 18663355.
12. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109(4):658-67, 2/2007. PMID: 17211865.

Grant & Contract Support

Title: Impact of ErbB2 and RB pathways on DCIS progression and treatment
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Agnes Witkiewicz
Duration: 7/1/2012 - 6/30/2017
 
Title: Protein Signaling Network in ER negative Breast cancer between AA and CA
Funding Source: NIH/NCI, New York University
Role: Consultant
Principal Investigator: Dr. Peng Lee
Duration: 2012
 
Title: DNA Damage As A Biomarker Of Risk Of Breast Cancer
Funding Source: UTMDACC IPCT
Role: Collaborator
Principal Investigator: Dr. Abenaa Brewster
Duration: 2012
 
Title: Serum MicroRNAs To Assess Breast Cancer Progression In BRCA and High Risk Patients
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Collaborator
Principal Investigator: Dr. Banu Arun
Duration: 2012
 
Title: CDK Inhibition and Smad3 Tumor Suppression in Aggressive Breast Cancer Subtypes
Funding Source: NIH/NCI, Northwestern University
Role: Collaborator
Principal Investigator: Dr. Jaqueline Jeruss
Duration: 2011
 
Title: Oncogene activation of DNA damage response as a biomarker of breast cancer risk and possible target for prevention
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Co-Investigator
Principal Investigator: Isabelle Bedrosian
Duration: 7/1/2010 - 6/30/2013
 
Title: Role of MicroRNA of the Annexin A1 Pathway in Breast Cancer Progression
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 5/1/2010 - 4/30/2013
 
Title: Aberrant Expression Of Mir-196 Targets Annexin A1 In In Situ And Invasive Breast Carcinomas: Potential Role In Breast Cancer Progression.
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 2010
 
Title: DCIS Collaborative Consortium
Funding Source: University of California, San Francisco
Role: Collaborator
Duration: 9/30/2009 - 9/29/2011
 
Title: Germline Mutation Of NHERF 2 and Its Network Genes In Hereditary Breast Cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Jiale Dai
Duration: 2009 - 2012
 
Title: Role Of MicroRNAs In Endometrial Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2009 - 2012
 
Title: Detection Of High Risk In Preneoplastic and Preinvasive Lesions of Breast Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2009 - 2012
 
Title: Early Markers Of High Risk In Premalignant Lesions Of Breast: Annexin A1 and MicroRNAs
Funding Source: Avon Foundation Breast Cancer Research Program
Role: Principal Investigator
Duration: 2009 - 2011
 
Title: Mechanisms Of Tumor Resistance To Anti-HER/Erbb Theraputics In Breast Cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Dr. Zhen Fan
Duration: 4/2/2008 - 1/31/2013
 
Title: MicroRNA Profiling To Identify Functional Targets Of Annexin A1 In Breast Cancer
Funding Source: Institutional Research Grant
Role: Principal Investigator-MDACC
Duration: 2/14/2007 - 6/14/2010
 
Title: Annexin In Primary And Metastatic Breast Carcinoma
Role: Career Development Award
Principal Investigator: Dr. Gabriel Hortobagyi
Duration: 2/14/2006 - 2/14/2007
 
Title: The Role Of Annexin A1 In Breast Cancer Cell Lines And Breast Cancer Tissues
Funding Source: Goodwin Foundation, Pilot Project, Commonwealth Foundation
Role: Principal Investigator
Duration: 10/2004 - 10/2005

Last updated: 7/28/2014